Rare diseases afflict 30 million Americans. Effectively marketing the orphan drugs that can treat these conditions means first understanding how drug pricing, R&D competition, and patient experience matter in the marketplace.
Drug approval numbers are up and biopharma continues to adapt. Still, “we may need to revisit the ODA to ensure that incentives remain to develop drugs for rare conditions and those incentives don't become diluted by loopholes,” says Nafeez Zawahir, MD, VP and scientific director at Discovery USA, in this Medical Marketing & Media article: Rare disease drugs facing questions over prices, incentives.
For a more in-depth look at the issues and further insights from Zawahir, check out the MM&M ebook Orphan Drug Marketing II: Data and expert insight for physician, patient, and payer outreach.